TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30569748
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg inhaled terbutaline
Study: 30569748
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg inhaled terbutaline
Study: 2714503
Drug: Lamicel with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamicel with intravenous oxytocin
Study: 2714503
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with intravenous oxytocin
Study: 21863638
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy de novo of adefovir dipivoxil (ADV) 10 mg per day and lamivudine (LMV) 100 mg per day
Study: 21863638
Drug: Monotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy of lamivudine (LMV) 100 mg per day
Study: 21863638
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy de novo of adefovir dipivoxil (ADV) and lamivudine (LMV)
Study: 21863638
Drug: Monotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy of lamivudine (LMV)
Study: 19255394
Drug: 4-hour adolescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour adolescent medicine workshop using standardized patients (n = 95)
Study: 15054026
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment (attendance of a course involving theoretical and practical sessions)
Study: 15054026
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (mailed information about BSE)
Study: 11388817
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (conjugated estrogens plus medroxyprogesterone)
Study: 8306923
Drug: Bromazepam 12
Normalized name: bromazepam 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 12 mg/d
Study: 8306923
Drug: Prazeapam 40
Normalized name: prazepam
DrugBank: Prazepam (DB01588)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazeapam 40 mg/d
Study: 30584287
Drug: Extracorporeal magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal magnetic innervation (ExMI) therapy, 15 minutes, three times a week for 4 weeks
Study: 30584287
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (ExMI therapy) vs Control group (no intervention)
Study: 26448141
Drug: Artefenomel 200
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 200 mg
Study: 26448141
Drug: Artefenomel 400
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 400 mg
Study: 26448141
Drug: Artefenomel 800
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 800 mg
Study: 26448141
Drug: Artefenomel 1200
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 1200 mg
Study: 26448141
Drug: Artefenomel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel (all doses)
Study: 22344065
Drug: Stretching of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching of the antagonist musculature
Study: 9740347
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training at 30% of maximum inspiratory mouth pressure for 30 min daily
Study: 8092115
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of metoclopramide (regimen A)
Study: 8092115
Drug: Intermittent short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent short infusion of metoclopramide (regimen B)
Study: 6214996
Drug: Moxalactam (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (500 mg every 12 h)
Study: 6214996
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g every 12 h)
Study: 27139726
Drug: Norepinephrine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 5 µg ml-1
Study: 27139726
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 µg ml-1
Study: 24622121
Drug: AAV1/SERCA2a gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV1/SERCA2a gene therapy
Study: 22935527
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in non-CKD (n=4,747)
Study: 22935527
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in mild CKD (n=2,135)
Study: 22935527
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in severe CKD (n=229)
Study: 22935527
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in HD (n=117)
Study: 19663622
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group (n = 68)
Study: 17464561
Drug: Esomeprazole, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole, 20 mg bid with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid for 1 week, followed by placebo for 3 weeks
Study: 17464561
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg bid with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid for 1 week, followed by omeprazole, 20 mg od for 3 weeks
Study: 15247714
Drug: PNB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNB plus rectal lidocaine gel
Study: 12566834
Drug: Intracystic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracystic chemotherapy with bleomycin (group A)
Study: 30488513
Drug: Coronary artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary artery bypass grafting surgery plus medical therapy
Study: 25931316
Drug: Pidotimod 400
Normalized name: pidotimod 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 400 mg per os twice daily for the last 10 days of each month from October 2013 to April 2014
Study: 19564809
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and intraurethral lidocaine
Study: 19564809
Drug: Topical lubricant
Normalized name: emollient base TOPICAL LUBRICANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lubricant control
Study: 15015186
Drug: EVAR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVAR with best medical treatment
Study: 11163386
Drug: Single-unit all-porcelain
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-unit all-porcelain crowns (SUAPC) preparation with acid etching
Study: 7828353
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (0.2 IU/kg/week for 6 months)
Study: 7828353
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (12 months)
Study: 7828353
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro glucocorticoid sensitivity during GH therapy
Study: 7828353
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm during open phase of GH therapy
Study: 3277478
Drug: Morphine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.25 mg (group I, n = 11)
Study: 3277478
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg (group II, n = 10)
Study: 22122992
Drug: Memantine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine treatment
Study: 12571662
Drug: Psyllium-enriched pasta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium-enriched pasta (1.7 g psyllium)
Study: 12571662
Drug: Pasta with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasta with 30 g sunflower oil and 3 g sodium propionate
Study: 30662380
Drug: Conventional one-on-one
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional one-on-one occupational therapy interventions
Study: 20122815
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with glutamine 0.18 g kg(‐1) d(‐1) for 20 d
Study: 17768157
Drug: Indometacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (0.2 mg/kg)
Study: 12701260
Drug: Subarachnoid anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid anesthesia with 5 mg of bupivacaine and 15 micrograms of fentanyl (Group F)
Study: 12701260
Drug: Subarachnoid anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid anesthesia with 7.5 mg bupivacaine (Group B)
Study: 8914088
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (10 mg)
Study: 8914088
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine with Vitamin C (250 mg)
Study: 1860146
Drug: Ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 100 micrograms/kg given at 2-week intervals for 6 doses
Study: 26450146
Drug: Hydrocortisone (H)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (H) 10 mg p.o. + placebo i.v.
Study: 26450146
Drug: Fludrocortisone (FC)
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (FC) 0.1 mg p.o. + placebo i.v.
Study: 26450146
Drug: Fludrocortisone (FC)
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (FC) 0.1 mg p.o. and Hydrocortisone (H) 10 mg p.o. + placebo i.v.
Study: 18271229
Drug: Blood-letting puncture
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-letting puncture at 12 Jing-well points of the hand combined with fuming and washing with herbal lotion
Study: 18271229
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diuretic
Study: 7585844
Drug: Risperidone (9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (9.4 mg/d for 1 year)
Study: 7585844
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 years treatment)
Study: 2262587
Drug: Chlorhexidine acetate
Normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine acetate (CHX) gum, 5 mg per piece, chewed 2 pieces 2 times daily for 10 min
Study: 2262587
Drug: Chlorhexidine acetate
Normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine acetate (CHX) gum, 4 mg per piece, chewed 2 pieces 2 times daily for 6 days
Study: 2262587
Drug: Chlorhexidine acetate
Normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine acetate (CHX) gum, 3 mg per piece, chewed 2 pieces 2 times daily for 6 days
Study: 2262587
Drug: Gum base
Normalized name: Gum base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum base without CHX or sweetening agent
Study: 31858394
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg) 5 min before induction, followed by infusion (2 mg/kg/h) until the end of surgery
Study: 31858394
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (placebo) and infusion of 0.9% saline solution during surgery
Study: 30996008
Drug: Hypofractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated stereotactic radiotherapy (HFSRT) concurrent with temozolomide (TMZ) at a dosage of 75 mg/m2 per day for at least 20 days
Study: 21658782
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of d,l-fenfluramine (FEN)
Study: 2526239
Drug: Cyclo provera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclo provera (Depo‐medroxy Progesterone Acetate 25 mg and Estradiol Cypionate 5 mg)
Study: 2526239
Drug: HRP-102 (Norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRP-102 (Norethisterone enanthate 50 mg and Estradiol Valerate 5 mg)
Study: 23607542
Drug: Oral vestibular
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vestibular cleansing capability assessment (measuring rice remaining in the oral vestibule)
Study: 19153091
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin daily starting on the first day of gonadotrophin stimulation
Study: 9778268
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral steroids
Study: 9778268
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (IFNbeta-1b) therapy
Study: 26228433
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with gemcitabine and cisplatin for 24 weeks
Study: 28388820
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine)
Study: 23755969
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (after switching therapies)
Study: 15013587
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (RT) with concurrent carboplatin/vindesine followed by surgery (arm A)
Study: 9840854
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tramadol
Study: 9840854
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg metoclopramide
Study: 9840854
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lidocaine
Study: 9840854
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL normal saline
Study: 8077826
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous injection of local anaesthetic beneath the cuff
Study: 2683281
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) - intravenous infusion of 1.5 million International Units during one hour
Study: 2683281
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (ASA) - 160 mg daily for 30 days
Study: 2683281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SK and ASA
Study: 2683281
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment only
Study: 335572
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium phosphate (MSP) 1, 3, 5, 10, 20, 30 mg/kg
Study: 335572
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MSS) 1, 3, 5, 10, 20, 30 mg/kg
Study: 335572
Drug: MSP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP and MSS (equal doses)
Study: 335572
Drug: MSP 30
Normalized name: hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [MSP-Blu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP 30 mg/kg
Study: 335572
Drug: MSP 40
Normalized name: hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [MSP-Blu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP 40 mg
Study: 335572
Drug: MSS 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSS 80 mg
Study: 335572
Drug: MSP 80
Normalized name: hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [MSP-Blu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP 80 mg
Study: 335572
Drug: MSP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP and MSS (equivalent doses)
Study: 30978155
Drug: Intermittent PEG-Asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent PEG-Asparaginase (3 doses at 6-week intervals)
Study: 30978155
Drug: Continuous PEG-Asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous PEG-Asparaginase (10 doses at 2-week intervals)
Study: 28549923
Drug: Consistently sufficient
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistently sufficient vitamin D group (25(OH)D >50 nmol/L at months 3 and 24)
Study: 28549923
Drug: Fluctuating vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluctuating vitamin D group (25(OH)D >50 nmol/L at either point)
Study: 28549923
Drug: Consistently insufficient
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistently insufficient vitamin D group (serum 25(OH)D ≤50 nmol/L at months 3 and 24)
Study: 19352339
Drug: Continuous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous adalimumab 40 mg every other week (e.o.w.)
Study: 19352339
Drug: Continuous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous adalimumab 40 mg every week
Study: 19352339
Drug: Induction dosing
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dosing followed by reinitiation of adalimumab
Study: 8355460
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) therapy
Study: 15226773
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention (NI) - intensive, individualised nutrition counselling by a dietitian using a standard protocol and oral supplements if required
Study: 9591224
Drug: tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 200 mg with immediate-release levodopa/carbidopa formulations
Study: 9591224
Drug: tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 200 mg with controlled-release levodopa/carbidopa formulation
Study: 7908624
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 MU thrice weekly) for one year
Study: 2892388
Drug: Oxprenolol and
Normalized name: oxprenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol and non-beta-blocker treatment
Study: 2892388
Drug: Beta-blocker-based therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker-based therapy
Study: 31750855
Drug: Marine ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine ω‐3 fatty acid, 1 g daily (including eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg)
Study: 31750855
Drug: Marine ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine ω‐3 fatty acid, 1 g daily
Study: 25843054
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1% THC)
Study: 25843054
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (4% THC)
Study: 25843054
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (7% THC)
Study: 23658394
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal capsular polysaccharide, CRM197 conjugate vaccine (PCV7)
Study: 21237188
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of lutein and 1 mg of zeaxanthin daily
Study: 19686995
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) preparation (90 mL in divided doses)
Study: 19686995
Drug: High-dose bisacodyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bisacodyl preparation (6 tablets of 5mg bisacodyl) plus water lavage (2 L of water)